Exogenous levodopa is not toxic to elderly subjects with non-parkinsonian movement disorders: Further clinical evidence

Journal of Neural Transmission

Volumn 106, Issue 3-4, 1999, Pages 301-307

  Hagenah, J ^a   Klein, C ^a   Sieberer, M ^a   Vieregge, P ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

Author keywords

Essential tremor; Levodopa; Neuroprotection; Oxidative stress; Parkinson's disease; Toxicity

Indexed keywords

LEVODOPA;

AGED; ARTICLE; CASE REPORT; CLINICAL FEATURE; ESSENTIAL TREMOR; FEMALE; GERIATRIC PATIENT; HUMAN; MOTOR DYSFUNCTION; NEUROPROTECTION; ORAL DRUG ADMINISTRATION; OXIDATIVE STRESS; PRIORITY JOURNAL; TIME;

AGED; AGED, 80 AND OVER; DIAGNOSTIC ERRORS; FEMALE; HUMANS; LEVODOPA; PARKINSON DISEASE; TREMOR;

EID: 0032891705     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/s007020050159     Document Type: Article

References (37)

1. Alexander T, Sortwell CE, Sladek CD, Roth RH, Steece-Collier K (1997) Comparison of neurotoxicity following repeated administration of l-dopa, d-dopa and dopamine to embryonic mesencephalic dopamine neurons in cultures derived from Fisher 344 and Sprague Dawley donors. Cell Transplant 6: 309-335
2. Anglade P, Vyas S, Javoy-Agid F, Herrero MT, Michel PP, Marquez J, Mouatt-Prigent A, Ruberg M, Hirsch EC, Agid Y (1997) Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease. Histol Histopathol 12: 25-31
3. Arts N, van de Vlasakker C, Tacke T, Horstink M (1991) Is levodopa harmful? Lancet 338: 1210-1211
4. Basma AN, Morris EJ, Nicklas WJ, Geller HM (1995) L-dopa cytotoxicity to PC12 cells in culture is via its autoxidation. J Neurochem 64: 825-832
5. Bedard PJ, Gomez Mancilla B, Blanchette P, Gagnon C, di Paolo T (1992) Levodopa-induced dyskinesia: Facts and fancy. What does the MPTP monkey model tell us? Can J Neurol Sci 19: 134-137
6. Blin J, Bonnet A-M, Agid Y (1988) Does levodopa aggravate Parkinson's disease? Neurology 38: 1410-1416
7. Boyce S, Rupniak NM, Steventon MJ, Iversen SD (1990) Nigrostriatal damage is required for induction of dyskinesias by L-dopa in squirrel monkeys. Clin Neuropharmacol 13: 448-458
8. 18F-dopa PET study. Neurology 42: 1554-1560
9. Cedarbaum JM, Grandy SE, McDowell FH (1989) Early initiation of levodopa treatment does not promote the development of motor response fluctuations, dyskinesias, or dementia in Parkinson's disease. Neurology 41: 622-629
10. Chang MH, Chang TW, Lai PH, Sy GG (1995) Resting tremor only: A variant of Parkinson's disease or of essential tremor. J Neurol Sci 130: 215-219
11. Cooper JM, Daniel SE, Marsden CD, Schapira AHV (1995) L-dihydroxyphenylalanine and complex I defiency in Parkinson's disease brain. Mov Disord 10: 295-297
12. De Jong GJ, Meerwaldt JD, Schmitz PIM (1987) Factors that influence the occurrence of response variations in Parkinson's disease. Ann Neurol 22: 4-7
13. Dziewczapolski G, Murer G, Agid Y, Gershanik O, Raisman-Vozari R (1997) Absence of neurotoxicity of chronic L-DOPA in 6-hydroxydopamine-lesioned rats. Neuroreport 8: 975-979
14. Fahn S (1996) Is levodopa toxic? Neurology 47 [Suppl 3]: S184-S195
15. Friedman A (1985) Levodopa-induced dyskinesia: Clinical observations. J Neurol 232: 29-31
16. Gibb WRG, Lees AJ (1988) The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 51: 745-752
17. 2 receptors in the monkey brain in MPTP-induced parkinsonism. Brain Res 602: 290-303
18. Jankovic J, Beach J, Schwartz K, Contant T (1995) Tremor and longevity in relatives of patients with Parkinson's disease, essential tremor, and control subjects. Neurology 45: 645-648
19. Lesser RP, Fahn S, Snider SR, Cote LJ, Isgreen WP, Barrett RE (1979) Analyses of the clinical problems in parkinsonism and the complications of long-term levodopa therapy. Neurology 29: 1253-1260
20. Mouradian MM, Heuser IJE, Baronti F, Fabbrini G, Juncos JL, Chase TN (1989) Pathogenesis of dyskinesias in Parkinson's disease. Ann Neurol 25: 523-526
21. Murer MG, Dziewczapolski G, Menalled LB, Garcia MC, Agid Y, Gershanik O, Raisman-Vozari R (1998) Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions. Ann Neurol 43: 561-575
22. Nutt JG (1990) Levodopa-induced dyskinesia: Review, observations, and speculations. Neurology 40: 340-345
23. Pardo B, Mena MA, Casarejos MJ, Paino CL, de Yebenes JG (1995) Toxic effects of L-dopa on mesencephalic cell cultures: Protection with antioxidants. Brain Res 682: 133-143
24. Poewe W, Gerstenbrand F (1986) Klinische Subtypen der Parkinson-Krankheit. Wien Med Wochenschr 136: 38-387
25. Poewe WH, Lees AJ, Stern GM (1986) Low-dose L-dopa therapy in Parkinson's disease: A 6-Year follow-up study. Neurology 36: 1528-1530
26. Przedborski S, Jackson-Lewis V, Fahn S (1995) Antiparkinsonian therapies and brain mitochondrial complex I activity. Mov Disord 10: 312-317
27. Quinn N, Parkes D, Janota I, Marsden CD (1986) Preservation of the substantia nigra and locus coeruleus in a patient receiving levodopa (2kg) plus decarboxylase inhibitor over a four-year period. Mov Disord 1: 65-68
28. Rajput AH, Rozdilsky B, Ang L, Rajput A (1991) Clinicopathologic observations in essential tremor: Report of six cases. Neurology 41: 1422-1424
29. Rajput AH, Fenton ME, Birdi S, Macaulay R (1997) Is levodopa toxic to human substantia nigra? Mov Disord 12: 634-638
30. Riley D (1998) Is levodopa toxic to the human substantia nigra? Mov Disord 13: 369-370
31. Singer C, Sanchez-Ramos J, Weiner WJ (1994) Gait abnormality in essential tremor. Mov Disord 9: 193-196
32. Vieregge P, Moser A (1992) Extrapyramidal-motorische Störungen und Depression unter Flunarizin-Therapie. Med Welt 43: 555-558
33. Walkinshaw G, Waters CM (1995) Induction of apoptosis in catecholaminergic PC12 cells by L-dopa: Implications for the treatment of Parkinson's disease. J Clin Invest 95: 2458-2464
34. Yahr MD, Wolf A, Antunes JL, Miyoshi K, Duffy P (1970) Autopsy findings in parkinsonism following treatment with levodopa. Neurology 6 [Suppl 1]: 55-66
35. Zetusky WJ, Jankovic J, Pirozzolo FJ (1985) The heterogeneity of Parkinson's disease: Clinical and prognostic implications. Neurology 35: 522-526
36. Zigmond MJ, Hastings TG, Abercrombie ED (1992) Neurochemical responses to 6-hydroxydopamine and L-dopa therapy: Implications for Parkinson's disease. Ann NY Acad Sci 648: 71-86
37. Ziv I, Zilkha-Falb R, Offen D, Shirvan A, Barzilai A, Melamed E (1997) Levodopa induces apoptosis in cultured neuronal cells - A possible accelerator of nigrostriatal degeneration in Parkinson's disease? Mov Disord 12: 17-23